

REPORTED August 27, 2026

CUSTOMER

NAME MapleBloom

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID: PT-015_D Received: 08/20/2026
Compound: PT-141 Analyzed: 08/27/2026
Report No.: COA-2026-SC-01521 CAS: 189691-06-3
Total Mass: 57.6 mg Formula: $C_{50}H_{68}N_{14}O_{10}$
Appearance: Lyophilized powder Mol Weight: 1025.2 g/mol

§ 02 Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	PT-141	PT-141	
Net Peptide Content:	10.00 mg	11.33 mg	
Peptide Label Accuracy:	≥ 90 %	113.3 %	PASS
Chromatographic Purity:	≥ 98 %	99.6 %	

Chromatographic purity is the target peptide's HPLC-MS/MS principal component analysis, expressed as a percentage of total integrated peak area (Ph. Eur. 2.2.46) — it bounds peptide-related impurities only, not excipients, counter-ions, or residual water, and is separate from net peptide content. — indicates not determined.

SAMPLE PHOTOGRAPH



SCAN TO VERIFY

COA-2026-SC-01521



VERIFICATION CODE
4Wquw60GHwN8uJBQ0ze71A
sidechainanalytics.com/verify

§ 03 LC-MS/MS Detail


METHOD A · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+

PRECURSOR [M+2H]²⁺

513.30 Da

Quantifier transition ● MRM

513.30 > 159.10 CE 25 V



ROLE	TRANSITION	CE
● Quantifier	513.3 > 159.1	25 V
■ Qualifier	513.3 > 175.1	32 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY

Results relate **only to the sample as received** and the tests performed — not to any other unit, lot, or batch. **For research use only:** not a certificate of quality, safety, efficacy, or regulatory compliance, and not for human or veterinary administration, clinical or diagnostic use, or label claims. SideChain Analytics does not manufacture, source, or sell the material and makes **no warranty, express or implied**; its liability shall not exceed the testing fee. This report may not be reproduced except in full.

REPORTED August 27, 2026

CUSTOMER

NAME MapleBloom

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID:	PT-016_D	Received:	08/20/2026
Compound:	PT-141	Analyzed:	08/27/2026
Report No.:	COA-2026-SC-01520	CAS:	189691-06-3
Total Mass:	57.1 mg	Formula:	$C_{50}H_{68}N_{14}O_{10}$
Appearance:	Lyophilized powder	Mol Weight:	1025.2 g/mol

§ 02 Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	PT-141	PT-141	
Net Peptide Content:	10.00 mg	11.82 mg	
Peptide Label Accuracy:	≥ 90 %	118.2 %	PASS
Chromatographic Purity:	≥ 98 %	99.7 %	

Chromatographic purity is the target peptide's HPLC-MS/MS principal component analysis, expressed as a percentage of total integrated peak area (Ph. Eur. 2.2.46) — it bounds peptide-related impurities only, not excipients, counter-ions, or residual water, and is separate from net peptide content. — indicates not determined.

SAMPLE PHOTOGRAPH

SCAN TO VERIFY
COA-2026-SC-01520VERIFICATION CODE
HFNXhiQo0zfYQT4am4ilgw
sidechainanalytics.com/verify

§ 03 LC-MS/MS Detail


METHOD A · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+

PRECURSOR [M+2H]²⁺

513.30 Da

Quantifier transition ● MRM

513.30 > 159.10 CE 25 V



ROLE	TRANSITION	CE
● Quantifier	513.3 > 159.1	25 V
■ Qualifier	513.3 > 175.1	32 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY

Results relate **only to the sample as received** and the tests performed — not to any other unit, lot, or batch. **For research use only:** not a certificate of quality, safety, efficacy, or regulatory compliance, and not for human or veterinary administration, clinical or diagnostic use, or label claims. SideChain Analytics does not manufacture, source, or sell the material and makes **no warranty, express or implied**; its liability shall not exceed the testing fee. This report may not be reproduced except in full.

REPORTED August 27, 2026

CUSTOMER

NAME MapleBloom

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID: PT-017_D Received: 08/20/2026
Compound: PT-141 Analyzed: 08/27/2026
Report No.: COA-2026-SC-01519 CAS: 189691-06-3
Total Mass: 58.9 mg Formula: $C_{50}H_{68}N_{14}O_{10}$
Appearance: Lyophilized powder Mol Weight: 1025.2 g/mol


§ 02 Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	PT-141	PT-141	
Net Peptide Content:	10.00 mg	10.14 mg	
Peptide Label Accuracy:	≥ 90 %	101.4 %	PASS
Chromatographic Purity:	≥ 98 %	99.6 %	

Chromatographic purity is the target peptide's HPLC-MS/MS principal component analysis, expressed as a percentage of total integrated peak area (Ph. Eur. 2.2.46) — it bounds peptide-related impurities only, not excipients, counter-ions, or residual water, and is separate from net peptide content. — indicates not determined.

SAMPLE PHOTOGRAPH



SCAN TO VERIFY

COA-2026-SC-01519



VERIFICATION CODE
iH0lmX1iTea9wXJaPmTCEg
sidechainanalytics.com/verify

§ 03 LC-MS/MS Detail


METHOD A · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+

PRECURSOR [M+2H]²⁺

513.30 Da

Quantifier transition ● MRM

513.30 > 159.10 CE 25 V



ROLE	TRANSITION	CE
● Quantifier	513.3 > 159.1	25 V
■ Qualifier	513.3 > 175.1	32 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY

Results relate **only to the sample as received** and the tests performed — not to any other unit, lot, or batch. **For research use only:** not a certificate of quality, safety, efficacy, or regulatory compliance, and not for human or veterinary administration, clinical or diagnostic use, or label claims. SideChain Analytics does not manufacture, source, or sell the material and makes **no warranty, express or implied**; its liability shall not exceed the testing fee. This report may not be reproduced except in full.